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Abstract
In this paper we present M4CVD: Mobile Machine Learning Model for Monitoring Cardiovascular Disease, a system designed
speciﬁcally for mobile devices that facilitates monitoring of cardiovascular disease (CVD). The system uses wearable sensors
to collect observable trends of vital signs contextualized with data from clinical databases. Instead of transferring the raw data
directly to the health care professionals, the system performs analysis on the local device by feeding the hybrid of collected data to
a support vector machine (SVM) to monitor features extracted from clinical databases and wearable sensors to classify a patient as
“continued risk” or “no longer at risk” for CVD. As a work in progress we evaluate a proof-of-concept M4CVD using a synthetic
clinical database of 200 patients. The results of our experiment show the system was successful in classifying a patient’s CVD risk
with an accuracy of 90.5%.
c© 2015 The Authors. Published by Elsevier B.V.
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1. Introduction
Cardiovascular Disease (CVD), which includes heart attack, stroke and hypertension, continues to be a leading
cause of death in the developed world1. While CVD related deaths in the developed world have recently decreased2,
chronic CVD continues to increase due to an aging population and rising obesity which is intensifying the eﬀects of
chronic disease3. In 2009, 1.6 million Canadians reported having heart disease4. CVD has also become a burden
on healthcare systems as the management of CVD is complex and requires continuous monitoring of the patients by
health professionals5. Remote patient monitoring is increasingly becoming an attractive solution for the management
of CVD. Patients and care providers can both beneﬁt from remote monitoring as it helps patients be more engaged in
their health through self-reported outcomes and provides support for cost-eﬀective care. Therefore there is a need for
a monitoring device for CVD patients that not only communicates collected data between remote patients and care
providers but also processes the raw data and summarizes that data in a meaningful way that helps health professionals
make more accurate and timely decisions when the patient is outside of the care settings. Such a device should yet be
usable and easily accessible by patients.
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Fig. 1. The proposed system architecture for monitoring cardiovascular disease
Due to the crucial role of remote monitoring for CVD patients, we have witnessed signiﬁcant eﬀorts from research
communities and industry to propose and design a variety of CVD monitoring devices. A number of devices reviewed
in this paper monitor single6,7 or multiple8,9 physiological signals using wearable sensors. Machine learning algo-
rithms (MLA) have been used to analyze physiological data to monitor CVD10 or analyze clinical databases to design
CVD diagnostic support systems11. Our review of the existing proposals on CVD monitoring devices show that they
do not automatically leverage the patient’s clinical data when analyzing the physiological data. Currently health pro-
fessionals implicitly use clinical data when examining the results from RPM systems. Furthermore, current systems
using MLAs perform analysis on remote servers requiring a constant network connection and cannot be used in poor
coverage zones in rural areas or low-income countries. The devices also require complex platforms with peripheral
devices as opposed to leveraging built in mobile device capabilities as we propose here. To address the gap in the
current devices we propose a system, designed speciﬁcally for mobile devices, that facilitates monitoring cardiovas-
cular disease. The system leverages built-in capabilities of mobile devices (e.g., computer processing capabilities,
activity tracking via accelerometers, health applications) plus wearable sensors to collect observable trends of vital
signs. The system also incorporates data from clinical databases to provide valuable contextual information for data
captured through physiological sensors. Instead of transferring the raw data directly to the professionals, the system
performs local analysis by feeding the hybrid of collected data to a support vector machine (SVM) to monitor features
extracted from clinical databases and wearable sensors. The system then classiﬁes a patient as “continued risk” or “no
longer at risk” for CVD. In this paper we build a proof-of-concept for our proposed cardiovascular monitoring system
called M4CVD: Mobile Machine-Learning Model for Monitoring Cardiovascular Disease. As a work in progress we
evaluate M4CVD using a synthetic clinical database of 200 patients. Our preliminary results show that the system
achieved a cross-validated accuracy of 90.5%.
The paper is structured as follows: Section 2 provides an overview of our proposed system and the speciﬁcations of
the four main components i.e., data collection, data processing, machine learning, and decision making. In Section 3
we report the experimental procedure and the results of the evaluation of M4CVD using synthetic sensor and clinical
data. In Section 4 we discuss the potential impact of the interpreted results on clinical decision improvement for the
patients outside of the clinical settings. Section 5 describes the related research. We conclude in Section 6.
2. Proposed System
In this section we present our proposed system as shown in Fig. 1. Using a SVM the system monitors features
extracted from wearable sensors and clinical databases. The system classiﬁes a patient as “continued risk” or “no
longer at risk” for CVD. The decision input and output data is transmitted to a server for storage and remote viewing.
Five components of the system architecture are Input, Data Processing, Machine Learning, Decision Making and
Output. Data Processing, Machine Learning and Decision Making are all performed on the mobile device.
2.1. Inputs
Our proposed system obtains input data from two sources: 1) physiological signals measured using wearable
sensors and 2) clinical data from health records. The system improves on previous devices which have been limited
to one input source. Physiological signals include electrocardiogram (ECG), blood pressure (BP), stress level through
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galvanic skin response (GSR) and accelerometers as an indicator of physical activity. Wearable sensors are worn
by the patient and the signals are collected by an embedded device such as a data acquisition microcontroller or
application-speciﬁc integrated circuit. The embedded device also preprocesses the data and transmits the sensor data
to the mobile device. Other sensors such as accelerometers are built into the mobile device themselves. Wearable
sensor data, which are not stored in clinical databases due to their large ﬁle size, allows for the examination of
observable long-term trends but lacks contextual information.
Our device will use clinical databases to provide context to physiological measurements. Databases will include
information such as age, gender, body mass index (BMI) and medication history. Databases also contain records of
physiological readings such as ECG, BP and SpO2. Clinical data is manually updated by healthcare professionals
during a patient’s visit. As a result clinical databases are updated less frequently compared to wearable systems and
any trends in the clinical data will take longer to be detected. In contrast to wearable sensors, databases contain records
on large patient populations which provides a large training set for the SVM. Through the combined input data, our
device will be able to rapidly interpret physiological measurements in the context of a patient’s medical history to
calculate the patient’s risk of CVD.
2.2. Data Processing
The input data must be processed into a set of features before becoming suitable inputs for a SVM. The processing
will be done through noise reduction, feature extraction and data normalization. Raw wearable sensor data contains
noise from both the environment and other biological signals that are not currently under observation. Motion artifacts
also aﬀect the raw data as the sensors are disturbed during day-to-day use. Noise and motion artifacts corrupt the
physiological signal and prevent useful feature extraction. Noise reduction will be completed with low/ high pass
ﬁlters to improve the signal-to-noise ratio12.
The second aspect of data processing is feature extraction. While continuous sensor data (e.g., ECG, accelerom-
eters) are used as input features to a SVM, our device will extract additional features from sensor data using signal
processing techniques. By using feature extraction we can convert continuous signals to discrete values. For example,
from an ECG signal we compute time domain features such as heart rate (HR) and R-R interval. ECG frequency
domain features include power spectral density and band power13.
While discrete features provide better inputs to the SVM there is still a challenge. The numeric ranges change
between the features as each reﬂects diﬀerent physiological values. During SVM training, features with larger ranges
may be assigned more weight over smaller feature ranges regardless of the importance of the feature to classiﬁcation
accuracy14. Normalizing the features to a range of (0,1) or assigning feature values to discrete categories (1,2,3,4)
eliminates this bias. For example, systolic blood pressure has a wide physiological range between 120-150 mmHg.
On the other hand, BMI has a smaller range of 16-50 kg/m2. Systolic blood pressure can be normalized by setting a
threshold value where the patient’s BP is either above (BP= 1) or below (BP=0) the threshold. BMI is represented by
categories of low, medium, high and highest risk (1,2,3,4). The features used for M4CVD will be from both clinical
and wearable data sets described by discrete or categorical classiﬁcations.
2.3. Machine Learning Algorithm
The next step as shown in Fig.1 is the design and training of the machine learning algorithm for the calculation
of a decision regarding patient risk. The support vector machine15, deﬁned in Eq.1, creates a classiﬁcation boundary
(hypersurface) to separate input vector xi into one of two classes yi  {0, 1}. The optimal SVM ﬁnds the w and b
that minimize the empirical error (risk) and the complexity of the classiﬁer, a trade-oﬀ achieved using the structural
risk minimization (SRM) principle16. In the training stage, the SVM is optimized using a set of input vectors xi with
known class labels yi. In the testing stage, new data vectors with unknown classes are then classiﬁed.
The Vapnik–Chervonenkis (VC) theory16 allows us to control the classiﬁer complexity in Eq.2 by minimizing
the classiﬁer margin,‖w‖, between the class boundary and the dividing hypersurface with bias b. The slack variable
ξ and the penalty constant C allows for some feature points to appear on the wrong side of the soft margin of the
hypersurface. As C → 0 more points are allowed to fall on the wrong side of the hypersurface which increases
generalization at the expense of training accuracy. When two classes are not linearly separable in 2D space a kernel
φ, deﬁned in Eq. 3, is used to map xi to a higher dimension features space φ(xi). A non-linear separating hypersurface
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yi(wTφ(xi) + b) ≥ 1 − ξi (1)
ξi ≥ 0
such that min
w,b,ξ
1
2
‖w‖2 +C
l∑
i=1
ξ (2)
k(x, xi) = φ(xiT )φ(xj) = exp(− 12σ2 ‖x − xi‖
2) (3)
is then constructed in the feature space. A popular kernel for SVMs is the radial basis function (RBF)17,18 and is
used when the number of training examples (i) is greater than the number of features (x) as is the case with our data.
The SVM and the kernel have two parameters that require optimization by the user: the penalty constant C, and the
kernel width σ2. The parameter selection is a balance between the SVM model’s training accuracy and generalization.
K-Fold cross validation is a procedure to determine the optimized C and σ2 by dividing the input data into K folds
and training the SVM on each K-1 fold and testing on Kth fold. A grid search of each unique combination ofC and σ2
is then conducted and the values that provide the best cross-validated classiﬁcation accuracy are chosen. A ﬁne grid
search focused around the optimized parameter selection from the broad grid search is conducted to further increase
accuracy. Once the SVM has been trained it can be applied to classify new data. Interested readers are referred to
Mu¨ller et al.19 for a more detailed explanation on SVM theory.
The SVM is a popular algorithm for our classiﬁcation situation due to its ability to map features to higher dimen-
sional data through a kernel function. The SVM was chosen because of its ability to construct a robust classiﬁer from
only a small data set. In addition it has good generalization properties allowing it to classify new data. SVMs have
been used in RPM systems to detect arrhythmia by comparing a patient’s current ECG with their baseline ECG20.
2.4. Decision Making and Output
The proposed MLA is trained with patients who are “continued risk” (Class 1) and “no longer at risk” (Class 0)
for heart disease. Class 1 patients are identiﬁed as needing further clinical intervention. Class 0 patients are those that
show positive response to treatment and are monitored to detect any relapses. The SVM creates a higher dimensional
space where a patient is either within the hypersurface (Class 1) or outside the hypersurface (Class 0)15. The SVM
has a binary output (0,1) which is interpreted and displayed to the user. The device allows patients to become a more
active contributor in their treatment plan as they can observe and monitor the results of the mobile MLA. The input
physiological and clinical data and resulting classiﬁcation decision are transmitted and stored in a remote server which
allows health care professionals to review results with or without the patient’s presence.
3. Experimental Procedure and Results
In this section we describe the experimental procedure for the M4CVD proof-of-concept. A synthetic database
containing thirteen features is created as described in Section 3.1. In Section 3.2 we describe how the SVM is
conﬁgured and trained on the synthetic patient records. The SVM results are described in Section 3.3 .
3.1. Experimental Setup of Data Collection
A database of 200 synthetic patient records was created using MATLAB. A synthetic database was chosen to allow
complete control on feature choice and feature distribution to provide a wide range of training scenarios for the SVM.
No signal processing was required on the synthetic features which did not suﬀer from noise or missing values. The
patient record contained features chosen with the help of a medical expert who subsequently diagnosed the synthetic
patient records. Each feature included in the database is a risk factor for cardiovascular disease21. The thirteen
features are shown in the ﬁrst column of Table 1. The second and third column of Table 1 shows that the features that
have been used in clinical databases22,23 as well as wearable sensors. The features represent either continuous (e.g.,
age, HR) or discrete (e.g., smoking, stress) vital signs. Each feature has a diﬀerent physiological range and level that
corresponds to an increased risk for CVD according to The Canadian Heart and Stroke Foundation21. For example,
the patient is at a higher risk of CVD if the patient’s cholesterol exceeds 5.2 mmol/L. Our database used a binary (0,1)
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value to represent the patient’s cholesterol level in regards to this threshold value in order to be a suitable SVM input
type as discussed in Section 2.2. Most of the risk factors except for age, HR and R-R interval are represented by a
binary or categorical values in reference to their physiological thresholds. HR and R-R interval remain continuous to
simulate the data collected from a wearable ECG sensor.
A single risk factor outside its physiological range is rarely suﬃcient to determine a patient’s overall level of CVD
risk. Rather it is the combination of all the patient’s risk factors. In order to eﬀectively train the SVM algorithm the
synthetic database contained a wide representation of many vital sign combinations. To achieve this, the features were
populated using MATLAB’s random generator library. The features were evenly distributed within their respective
physiological ranges to maximize the number of patient records with diﬀerent feature combinations. Initially, age and
BMI, two major risk factors, were also randomly and evenly distributed over certain physiological ranges. However,
this resulted in a low patient population that was no longer at risk for CVD (7%). Age24 and BMI25 were then
populated based on census data to better represent population distribution. Using the new distributions for age and
BMI (Fig.2) the number of “no longer at risk” patients increased to 21.5% which indicates that accurate feature
distribution is important when creating the database.
Table 1 (last column) shows each feature’s distribution within the database. Each possible feature value was
uniformly represented in the database which limits the bias towards speciﬁc conditions. Such a uniform distribution
increases the number of unique feature combinations when examining the patient records. The resulting SVM training
set contains a wide variety of patient data. The database contained 157 patients classiﬁed as “continued risk” (78.5%),
and 43 patients “no longer at risk” (21.5%) which is a fair representation of a real population as CVD is a chronic
disease and patient’s in this type of database are at an increased risk of CVD. The high proportion of “continued risk”
patients indicates that there are far more combination of features that results in a “continued risk” patient compared
to a “no longer at risk” patient.
Table 1. Each patient’s electronic health record in the database contains simulated data for thirteen vital signs
Feature ClinicalDatabase?
Wearable
Sensor?
Physiological
Range
SVM
Normalization Distribution
Age Y N 30-80 years Continuous
Gender Y N Male, Female 0 , 1 47.0% / 53.0%
Body Mass Index Y N
Normal <24 kg/m2
Overweight 25-29.9 kg/m2
Obese I 30-39.9 kg/m2
Obese II >40 kg/m2
1
2
3
4
Smoker Y N Yes, No 0 , 1 53.5% / 46.5%
Exercise Y Y Yes, No 0 , 1 47.5% / 52.5%
Stress (GSR) Y Y Yes, No 0 , 1 45.5% / 54.5%
Resting heart rate (ECG) Y Y Normal 60-100 beats/minAbnormal >100 beats/min Continuous
Systolic Blood Pressure Y Y
Low Risk <120 mmHg
Medium Risk 121-139 mmHg
High Risk >140 mmHg
0
1
2
30.5%
34.5%
35.0%
Diastolic Blood Pressure Y Y
Low Risk <80 mmHg
Medium Risk 80-89 mmHg
High Risk >90 mmHg
0
1
2
29.5%
34.5%
36.0%
Total Cholesterol Y N Low Risk <5.2 mmol/LHigh Risk >5.2 mmol/L
0
1
50.0%
50.0%
Low Density Lipoproteins (LDL) Y N Low Risk >3.5 mmol/LHigh Risk <3.5 mmol/L
0
1
52.0%
48.0%
High Density Lipoproteins (HDL) Y N Low Risk >1 mmol/LHigh Risk <1 mmol/L
0
1
47.0%
53.0%
R-R Interval N Y Normal 0.4-1.5 secsAbnormal >1.5 secs Continuous
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Fig. 2. The distribution of BMI, age and resting heart rate in the database
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Fig. 3. SVM CV to optimize C and σ selection (C=100 and σ= 2)
3.2. Experimental Setup of Machine Learning Algorithm
All 200 patient records were used to train the SVM. The RBF kernel has two parameters to conﬁgure: 1) the
penalty constant C and 2) kernel width σ2. A cross-validation was used to train the SVM where the training data is
divided into 5 folds (groups). For each (C, σ2) combination, ﬁve SVMs were generated using a diﬀerent group as
the testing set and the remaining groups as the training set. The average SVM accuracy was obtained by taking the
average accuracy over each unique SVM for a given (C, σ2) pair. The procedure was repeated for a grid search of
a combination of C and σ2 pairs. The pair that provided the best average classiﬁcation accuracy was chosen. The
MATLAB machine learning toolbox was used to implement the SVM.
3.3. Results
Figure 3 shows the accuracy of the SVM over diﬀerent (C,σ) combinations. The optimal SVM had an accuracy
of 90.5% and training time was 90 seconds. As σ2 increased the model achieves higher accuracy and increased
generalization. However after the peak value, σ=2, the model becomes over ﬁtted and accuracy falls. As C increases
the penalty for misclassiﬁcation goes up. At ﬁrst, increasing this penalty (allowing less points to fall on the wrong
side of the hyperspace) increases accuracy. However over penalizing lowers the generalization of the algorithm. The
graph in Fig. 3 can be used to conﬁgure the model for optimized accuracy and generalization. Using cross-validation
is an analytical approach to determining this optimal point. We can also modify the parameter selection to favor either
accuracy or generalization depending on the design requirements.
4. Discussion
Our ﬁrst steps towards developing M4CVD was testing a proof-of-concept system which achieved an accuracy
of 90.5%. The system was successful in classifying a patient’s CVD risk based on data from a synthetic database.
Analyzing 200 patients would take a human several hours to complete while the SVM could analyze all the records
in less than one hour. The results support the hypothesis that data mining techniques can be used on input data from
wearable sensors and clinical databases.
The model also exhibits some limitations. When the medical expert classiﬁed the records BMI, smoking, choles-
terol and BP emerged as major factors that had a bigger inﬂuence on a patient’s classiﬁcation compared to the re-
maining attributes. If any one of these features were signiﬁcantly above the acceptable level it increased the patient’s
chance of being classiﬁed as at “continued risk” for CVD. Patients exhibiting multiple major features that were only
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slightly above the acceptable level had an even higher chance of being classiﬁed as at risk. However, patients with
minor factors (e.g., stress, exercise) greatly above the acceptable level were still classiﬁed “low risk” as long as the
major factors were at safe levels. Minor factors were used when classifying borderline patients and so could not be
entirely discounted.
Table 2 shows a patient record classiﬁed as “at continued risk” for CVD due to the presence of just two major
features: cholesterol and BP. Patient 30 is a good candidate for cardiovascular treatment by using medication to lower
her BP which should result in reclassiﬁcation to “low risk”. We can test the sensitivity of the system by modifying
Patient 30’s record and retesting the patient’s classiﬁcation level. Patient 30 demonstrates the diﬃculty in the binary
classiﬁcation as overall CVD risk in medicine is described using multiple risk levels. Patient 30 is not the most severe
case in the database while other patients were borderline but were still classiﬁed healthy. In these cases the patients
lie very close to hypersurface that divides the two classes which could lead to misclassiﬁcations. A multiclass SVM
model could instead be used to provide health practitioners with a three class monitoring scale of low, medium and
high risk.
Table 2. A sample patient record from the clinical database
Patient 30 Record from Database
Age 47 Smoking N Resting Heart Rate 100 beats/min Total Cholesterol High Risk R-R 1.12 sec
Gender Female Excercise N Systolic Blood Pressure Medium Risk LDL Cholesterol High Risk Interval
Weight Normal Stress N Diastolic Blood Pressure High Risk HDL Cholesterol High Risk
5. Related Work
Multiple devices record ECG for extended periods of time such as CardioNet6, a commercial wearable ECG plat-
form, and UUTE7, a proposed mobile phone ECG monitor. As these systems only measure a single physiological
signal without contextual information they are unable to provide complete information on CVD risk. An improvement
on these single monitoring devices are systems such as SmartVest8 and AMON9. Both contain sensors for multiple
physiological risk factors (e.g., ECG, BP) inside a t-shirt and wrist device respectively. SmartVest is solely a signal ac-
quisition device. AMON goes beyond data acquisition to assist the physician by displaying only abnormal recordings.
While AMON shows limited data interpretation it does not consider the eﬀect of all physiological readings together
and does not integrate clinical database information.
The development of monitoring technology has resulted in the recording of large amounts of physiological data
increasing the need for eﬀective analysis techniques. Our device will utilize an MLA to analyze the collected data.
MLAs have been applied in the medical ﬁeld for screening, diagnosis, treatment, prognosis, monitoring and disease
management26. Previous work by Pecchia et al. developed a CVD management program to determine heart failure
severity10. The system used a classiﬁcation and regression tree trained on database of physiological data and achieved
an accuracy of 96.39% . The system demonstrates the feasibility of using MLAs in a monitoring system. However,
the system was not implemented on a mobile device and did not analyze clinical data.
Mobile phones have been shown to have the computational power to support MLAs. Oresko et al. presented
HeartToGo, a mobile phone that performed data acquisition, feature extraction and classiﬁcation of ECG signals27.
The system used MLAs and achieved an accuracy of 90% in real-time CVD detection but monitored a single wearable
sensor. Our device will improve on HeartToGo by measuring multiple sensors and including clinical data.
Current monitoring systems face a number of limitations and focus primarily on data acquisition without con-
ducting local analysis. Our proposed device will improve upon existing CVD monitoring systems by increasing the
monitored input data and by using an MLA to perform data analysis on a mobile device. While previous work has
proven the eﬀectiveness of the individual components of our device, no work has integrated these characteristics.
6. Conclusion and Future Work
In this paper, we have demonstrated a new system for the monitoring of cardiovascular disease. The proposed
system is based on the SVM which analyzes features extracted from wearable sensors and clinical databases. Such a
systemwill assist health care professionals by presenting relevant and summarized information on a patient’s condition
from all of the collected data. The proof-of-concept system successfully classiﬁed a patient’s risk level using synthetic
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data. In view of these results, we are implementing this system on a mobile device using real data from clinical
databases and wearable sensors. The monitoring device will be evaluated by its accuracy in classifying live monitored
data. We are investigating methods to test the system’s sensitivity to changing patient conditions. Furthermore we
will test the system’s performance with other MLAs such as neural networks and multi-class SVMs.
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